Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of maraviroc in the treatment of rheumatoid arthritis in subjects receiving methotrexate

Next Previous
X
Search
Trial Profile

A phase 2, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of maraviroc in the treatment of rheumatoid arthritis in subjects receiving methotrexate

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maraviroc (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 18 Oct 2009 Results presented at ACR 2009.
    • 29 Sep 2008 Status changed from recruiting to discontinued according to the ClinicalTrials.gov record.
    • 29 Sep 2008 Actual number of patients enrolled 129 according to the ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top